BRAF and melanoma: In the COLUMBUS phase III clinical trial, previously treated or untreated advanced-stage melanoma patients harboring BRAF exon 15 p.V600E or p.V600K point mutations were randomly assigned to receive the combination regimen or single BRAF inhibitor therapies (vemurafenib or encorafenib).